IPP Bureau
Alembic Pharmaceuticals partners with Enthral.ai for learning and training management of its 9000+ learners
By IPP Bureau - April 02, 2026
Enthral.ai’s platform integrates AI-driven capabilities with compliance-first architecture, enabling automated training workflows
Glenmark Pharmaceuticals accelerates U.S. strategy with direct RYALTRIS distribution
By IPP Bureau - April 02, 2026
This marks a meaningful step in the company's continued expansion in the region
FICCI Advantage Healthcare India 2026 honours Fortis Bannerghatta as top kidney transplant centre
By IPP Bureau - April 02, 2026
A key milestone in this journey has been the introduction of TREAT Program, a first-of-its-kind clinical initiative introduced in India
Molbio’s digital radiology arm secures CE MDR certification for its medical imaging portfolio
By IPP Bureau - April 02, 2026
Certification by TÜV SÜD Product Service GmbH reinforces the company's commitment to globally benchmarked standards in safety, quality, and performance
D2C nutrition brand BeastLife raises Rs 20 crore at Rs 320 crore valuation from GVFL and Equentis
By IPP Bureau - April 02, 2026
The company has achieved a turnover of around Rs 100 crore in FY 2025–26 and aims to achieve a turnover of Rs 500 crore in next three years
Vyome Holdings bolsters financial position to support VT-1953 pivotal study through 2027
By IPP Bureau - April 02, 2026
As of December 31, 2025, the company reported total cash, cash equivalents and short-term investments of approximately $4.94 million
FDA okays Eli Lilly’s new weight-loss pill, expanding options for millions
By IPP Bureau - April 02, 2026
The approval is backed by results from Lilly’s ATTAIN clinical trial program, which showed significant weight loss among participants
Bayer plans to offer Eylea 2mg at lower cost in India for benefit of retinal disease patients
By IPP Bureau - April 02, 2026
Eylea 2mg (intravitreal aflibercept injection) is an anti-VEGF therapy that blocks a protein responsible for abnormal blood vessel growth and leakage in the retina
Lupin completes acquisition of VISUfarma
By IPP Bureau - April 02, 2026
The move represents a significant milestone in Lupin’s strategy to expand its specialty care portfolio and strengthen its presence in Europe
Agilent opens new customer experience center in Mumbai
By IPP Bureau - April 02, 2026
The center brings together hands on technology demonstrations, application expertise, and commercial operations
Emcure Pharma reduces Poviztra starting dose price by 55% in India
By IPP Bureau - April 02, 2026
The price revision, effective April 3, 2026, brings the innovator molecule within the reach of a significantly larger patient base across the country
Orca Bio’s Orca-T FDA review extended to July 2026
By IPP Bureau - April 02, 2026
Biogen to buy Apellis Pharmaceuticals for $5.6B in rare disease and immunology push
By IPP Bureau - April 02, 2026
The acquisition brings two commercialized, differentiated medicines—EMPAVELI and SYFOVRE —to Biogen’s growth portfolio
Middle East disruption hits thousands of global clinical trials, Phesi warns
By IPP Bureau - April 02, 2026
The impact on Phase III trials is particularly significant, as these later-stage studies involve larger, committed patient populations and represent years of investment
Biogen bags FDA nod for high dose SPINRAZA in spinal muscular atrophy
By IPP Bureau - April 02, 2026
The new regimen, delivering 50 mg/5 mL and 28 mg/5 mL doses, offers a higher concentration of the drug for both loading and maintenance phases
